Sam Brusco, Associate Editor12.19.23
Carl Zeiss Meditec began a deal to acquire 100% of the shares in Dutch Ophthalmic Research Center (D.O.R.C.) from Paris investment firm Eurazeo SE. The deal is valued at about €985 million and is expected to close in H1 2024.
D.O.R.C. is a provider of retinal surgical devices, enhancing and complementing Carl Zeiss’ ophthalmic portfolio and range of connected workflow solutions for eye conditions. D.O.R.C.’s portfolio of devices, disposables, and ophthalmic surgery liquids are poised to expand Zeiss’ position in vitreo-retinal (VR) surgery.
The EVA NEXUS platform is D.O.R.C.’s dual-function system and includes a range of accessories, instruments, and liquids for VR, cataract, and combined procedures.
"With the acquisition of Dutch Ophthalmic Research Center, we'll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS's position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market," said Dr. Markus Weber, president and CEO of Carl Zeiss.
"In the year when D.O.R.C. celebrates 40 years of innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology," added Pierre Billardon, CEO of D.O.R.C. "We've built an amazing business with innovative, market-leading products and look forward to seizing this opportunity for growth and advancing the future of ophthalmic surgery. I am personally proud and immensely grateful to all of the team at D.O.R.C. for their commitment and expertise to help patients see again."
D.O.R.C. is a provider of retinal surgical devices, enhancing and complementing Carl Zeiss’ ophthalmic portfolio and range of connected workflow solutions for eye conditions. D.O.R.C.’s portfolio of devices, disposables, and ophthalmic surgery liquids are poised to expand Zeiss’ position in vitreo-retinal (VR) surgery.
The EVA NEXUS platform is D.O.R.C.’s dual-function system and includes a range of accessories, instruments, and liquids for VR, cataract, and combined procedures.
"With the acquisition of Dutch Ophthalmic Research Center, we'll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS's position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market," said Dr. Markus Weber, president and CEO of Carl Zeiss.
"In the year when D.O.R.C. celebrates 40 years of innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology," added Pierre Billardon, CEO of D.O.R.C. "We've built an amazing business with innovative, market-leading products and look forward to seizing this opportunity for growth and advancing the future of ophthalmic surgery. I am personally proud and immensely grateful to all of the team at D.O.R.C. for their commitment and expertise to help patients see again."